


Emedastine difumarate

Cat. No.:	HY-B2178
CAS No.:	87233-62-3
Molecular Formula:	C ₂₅ H ₃₄ N ₄ O ₉
Molecular Weight:	534.56
Target:	Histamine Receptor
Pathway:	GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Emedastine difumarate is an orally active, selective and high affinity histamine H ₁ receptor antagonist with a K _i value of 1.3 nM. Emedastine difumarate is a benzimidazole derivative with potent antiallergic properties and used for allergic rhinitis, allergic skin diseases and allergic conjunctivitis ^{[1][2][3]} .										
IC₅₀ & Target	H ₁ Receptor 1.3 nM (K _i)	H ₂ Receptor 49067 nM (K _i)	H ₃ Receptor 12430 nM (K _i)								
In Vitro	<p>Emedastine difumarate inhibits histamine H₂ receptor (K_i=49067 nM) and histamine H₃ receptor (K_i=12430 nM)^[1]. High concentrations of Emedastine difumarate (1 and 10 ng/ml) significantly inhibits type 1 collagen production in normal human dermal fibroblasts^[2].</p> <p>Emedastine difumarate (1, 10, 100, 1000 nM) at concentrations of ≥ 10 nM inhibits CC chemokine-elicited eosinophil migration^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>										
In Vivo	<p>Emedastine difumarate (0.03, 0.1, 0.3 mg/kg; orally; pretreatment of 30 min) significantly suppresses histamine-induced scratching with 0.1 and 0.3 mg/kg but not 0.03 mg/kg^[3].</p> <p>Pretreatment with Emedastine difumarate (0.03, 0.1, 0.3 mg/kg; orally) significantly inhibits the scratching induced by substance P and leukotriene B^[3].</p> <p>Emedastine difumarate (0.3 mg/kg, p.o.) produces significant inhibition of passive peritoneal anaphylaxis in guinea-pigs^[2]. Emedastine difumarate inhibits histamine-induced contractions of isolated ileum (IC₅₀=6.1 nM)^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male ICR mice 5-6 weeks of age^[3]</td> </tr> <tr> <td>Dosage:</td> <td>0.03, 0.1, 0.3 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Orally; 30 min before pruritogen injection</td> </tr> <tr> <td>Result:</td> <td>Significantly suppressed histamine-induced scratching with pretreatment of 0.1 and 0.3 mg/kg.</td> </tr> </table>			Animal Model:	Male ICR mice 5-6 weeks of age ^[3]	Dosage:	0.03, 0.1, 0.3 mg/kg	Administration:	Orally; 30 min before pruritogen injection	Result:	Significantly suppressed histamine-induced scratching with pretreatment of 0.1 and 0.3 mg/kg.
Animal Model:	Male ICR mice 5-6 weeks of age ^[3]										
Dosage:	0.03, 0.1, 0.3 mg/kg										
Administration:	Orally; 30 min before pruritogen injection										
Result:	Significantly suppressed histamine-induced scratching with pretreatment of 0.1 and 0.3 mg/kg.										

REFERENCES

-
- [1]. Sharif NA, et al. Emedastine: a potent, high affinity histamine H1-receptor-selective antagonist for ocular use: receptor binding and second messenger studies. J Ocul Pharmacol. 1994 Winter;10(4):653-64.
- [2]. Murota H, et al. Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases. Expert Opin Pharmacother. 2009 Aug;10(11):1859-67.
- [3]. Andoh T, et al. Involvement of blockade of leukotriene B(4) action in anti-pruritic effects of emedastine in mice. Eur J Pharmacol. 2000 Oct 6;406(1):149-52.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA